Arcus Biosciences, Inc. (RCUS) Stock Price

RCUSStock

$22.12+33.25%52W

Market Cap$2.82B

P/E—

PEG Ratio—

Div yield—

Beta1.06

RCUS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-13.77%

Price vs S&P 500 (4W)-13.43%

VGM Score38.86

Book Value / Share (Quarterly)$3.65

P/TBV (Annual)1.60x

Revenue Growth (3Y)30.16%

Cash Flow / Share (Quarterly)$-3.74

Price vs S&P 500 (YTD)-19.10%

Net Profit Margin (TTM)-393.16%

EPS (TTM)$-3.90

10-Day Avg Trading Volume1.31M

EPS Excl Extra (TTM)$-3.90

Revenue Growth (5Y)26.09%

EPS (Annual)$-3.29

ROI (Annual)-48.36%

Net Profit Margin (5Y Avg)-147.92%

Cash / Share (Quarterly)$5.53

Revenue Growth QoQ (YoY)-74.38%

ROA (Last FY)-30.99%

Revenue Growth TTM (YoY)-50.00%

EBITD / Share (TTM)$-4.00

ROE (5Y Avg)-43.02%

Operating Margin (TTM)-415.38%

Cash Flow / Share (Annual)$-3.86

P/B Ratio6.07x

P/B Ratio (Quarterly)8.36x

Net Income / Employee (Annual)$-587,400

EV / Revenue (TTM)23.65x

ROA (TTM)-45.61%

EV / EBITDA (TTM)34.00x

EPS Incl Extra (Annual)$-3.29

Current Ratio (Annual)4.36x

Quick Ratio (Quarterly)3.75x

3-Month Avg Trading Volume1.41M

52-Week Price Return33.25%

Revenue / Employee (TTM)$194,700

Tangible BV / Share (Quarterly)$6.95

P/S Ratio (Annual)11.40x

Asset Turnover (Annual)0.22x

52-Week High$31.73

Operating Margin (5Y Avg)-162.13%

EPS Excl Extra (Annual)$-3.29

CapEx CAGR (5Y)-8.39%

Tangible BV CAGR (5Y)33.69%

26-Week Price Return-3.87%

Quick Ratio (Annual)4.32x

13-Week Price Return-19.18%

Total Debt / Equity (Annual)0.16x

Current Ratio (Quarterly)3.82x

Enterprise Value$2.77B

Revenue / Share Growth (5Y)10.21%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-8.18%

Revenue / Employee (Annual)$411,000

Pretax Margin (Annual)-142.91%

Cash / Share (Annual)$7.83

3-Month Return Std Dev46.13%

Net Income / Employee (TTM)$-765,400

ROE (Last FY)-55.94%

EPS Basic Excl Extra (Annual)$-3.29

P/FCF (TTM)112.66x

Receivables Turnover (TTM)3.84x

Total Debt / Equity (Quarterly)0.22x

EPS Incl Extra (TTM)$-3.90

Receivables Turnover (Annual)12.05x

ROI (TTM)-75.01%

P/S Ratio (TTM)24.07x

Pretax Margin (5Y Avg)-146.54%

Revenue / Share (Annual)$2.30

Tangible BV / Share (Annual)$9.01

Price vs S&P 500 (52W)17.72%

Year-to-Date Return-7.18%

5-Day Price Return-9.12%

EPS Normalized (Annual)$-3.29

ROA (5Y Avg)-20.03%

Net Profit Margin (Annual)-142.91%

Month-to-Date Return-14.36%

Cash Flow / Share (TTM)$-3.91

EBITD / Share (Annual)$-3.50

Operating Margin (Annual)-156.28%

LT Debt / Equity (Annual)0.16x

ROI (5Y Avg)-40.46%

LT Debt / Equity (Quarterly)0.22x

EPS Basic Excl Extra (TTM)$-3.90

P/TBV (Quarterly)2.02x

P/B Ratio (Annual)4.67x

Pretax Margin (TTM)-393.16%

Book Value / Share (Annual)$5.04

Price vs S&P 500 (13W)-21.87%

Beta1.06x

P/FCF (Annual)6.52x

Revenue / Share (TTM)$0.93

ROE (TTM)-89.54%

52-Week Low$16.04

vGradeD

gGradeD

mGradeB

vgmGradeD

RCUS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.81	-$0.72	+11.58%(+$0.09)
Q1 2026	May 5, 2026	-$0.83	-$1.02	-23.26%(-$0.19)
Q4 2025	Feb 25, 2026	-$1.07	-$0.89	+17.21%(+$0.18)
Q3 2025	Oct 28, 2025	-$1.29	-$1.27	+1.58%(+$0.02)
Q2 2025	Aug 6, 2025	-$1.17	$0.00	+100.00%(+$1.17)

RCUS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.06

4.05

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RCUSArcus Biosciences, Inc.	D	D	B	24.1x	-50.0%	—	—	$22.12
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Arcus Biosciences, Inc.

Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated molecular therapies for cancer and inflammatory and autoimmune diseases. The company's pipeline includes several investigational drug candidates designed to address unmet medical needs in these therapeutic areas.

RCUS Next Earnings Report

Report dateOct 27, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.87

Revenue estimate$11.94M

Also reporting on Oct 27, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

RCUS Insider Transactions

SellAug 21, 2026
AZOY ALEXANDER
Officer
Shares: 2,827Value: $84,810

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products
SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals
COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals
NEOGNeogen CorpIn Vitro Diagnostics

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$16.04

High$31.73